Patents Assigned to Clene Nanomedicine, Inc.
  • Publication number: 20210361699
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
    Type: Application
    Filed: April 13, 2021
    Publication date: November 25, 2021
    Applicant: Clene Nanomedicine, Inc.
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
  • Publication number: 20210236542
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
    Type: Application
    Filed: April 6, 2021
    Publication date: August 5, 2021
    Applicant: Clene Nanomedicine, Inc.
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
  • Patent number: 10980832
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: April 20, 2021
    Assignee: Clene Nanomedicine, Inc.
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
  • Publication number: 20210052638
    Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 25, 2021
    Applicant: Clene Nanomedicine, Inc.
    Inventors: David Kyle Pierce, Mark G. Mortenson, David A. Bryce
  • Publication number: 20200188429
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
    Type: Application
    Filed: August 8, 2019
    Publication date: June 18, 2020
    Applicant: Clene Nanomedicine, Inc.
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
  • Patent number: 10449217
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: October 22, 2019
    Assignee: Clene Nanomedicine, Inc.
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
  • Patent number: 10441608
    Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: October 15, 2019
    Assignee: Clene Nanomedicine, Inc.
    Inventors: David Kyle Pierce, Mark G. Mortenson, David A. Bryce
  • Publication number: 20190059386
    Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. The continuous process causes at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s).
    Type: Application
    Filed: August 31, 2018
    Publication date: February 28, 2019
    Applicant: Clene Nanomedicine, Inc.
    Inventors: David K. Pierce, Mark G. Mortenson, David A. Bryce
  • Publication number: 20190009342
    Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s) (e.g., colloids). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. Processing enhancers can be utilized alone or with a plasma. Semicontinuous and batch processes can also be utilized.
    Type: Application
    Filed: July 16, 2018
    Publication date: January 10, 2019
    Applicant: Clene Nanomedicine, Inc.
    Inventors: David Kyle Pierce, Mark Gordon Mortenson, David Andrew Bryce, Adam Robert Dorfman, Mikhail Merzliakov, Arthur Maxwell Grace
  • Patent number: 10092007
    Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. The continuous process causes at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s).
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 9, 2018
    Assignee: Clene Nanomedicine, Inc.
    Inventors: David K. Pierce, Mark G. Mortenson, David A. Bryce
  • Patent number: 10035192
    Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s) (e.g., colloids). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. Processing enhancers can be utilized alone or with a plasma. Semicontinuous and batch processes can also be utilized.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: July 31, 2018
    Assignee: Clene Nanomedicine, Inc.
    Inventors: David Kyle Pierce, Mark Gordon Mortenson, David Andrew Bryce, Adam Robert Dorfman, Mikhail Merzliakov, Arthur Maxwell Grace
  • Publication number: 20170367345
    Abstract: This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. The continuous process causes at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s).
    Type: Application
    Filed: August 11, 2017
    Publication date: December 28, 2017
    Applicant: Clene Nanomedicine, Inc.
    Inventors: David K. Pierce, Mark G. Mortenson, David A. Bryce
  • Publication number: 20170348350
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
    Type: Application
    Filed: March 21, 2017
    Publication date: December 7, 2017
    Applicant: Clene Nanomedicine, Inc.
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov